FCGR2A rs1801274 polymorphism is associated with response to natalizumab in multiple sclerosis patients
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
FCGR2A rs1801274 polymorphism is associated with response to natalizumab in multiple sclerosis patients ; volume:82 ; number:S 01 ; year:2024 ; 01
Konferenz: 25th BCTRIMS Annual Meeting; 2024-06-05; Tivoli Mofarrej São Paulo - SP
Arquivos de neuro-psiquiatria ; 82, Heft S 01 (2024), 01
- Contributor
-
de Matos, Matheus D.
Cardoso, Rafaella C.
Duarte, Larissa A.
Guimenez, Barbara D.
Pavani, Giovanni K.
Fernandez, Kamilla A.
Farinhas, João Gabriel Dib
Schmidt, Felipe da R.
Montes, Guillherme C.
Alves-Leon, Soniza V.
Fontes-Dantas, Fabricia L.
- DOI
-
10.1055/s-0044-1789375
- URN
-
urn:nbn:de:101:1-2412121011076.389213668979
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:26 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- de Matos, Matheus D.
- Cardoso, Rafaella C.
- Duarte, Larissa A.
- Guimenez, Barbara D.
- Pavani, Giovanni K.
- Fernandez, Kamilla A.
- Farinhas, João Gabriel Dib
- Schmidt, Felipe da R.
- Montes, Guillherme C.
- Alves-Leon, Soniza V.
- Fontes-Dantas, Fabricia L.
Other Objects (12)
GP6 rs2304166 polymorphism is associated with response to natalizumab in multiple sclerosis patients
Natalizumab May Improve Cognition and Mood in Multiple Sclerosis
Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists
Pharmacogenomics of clinical response to Natalizumab in multiple sclerosis: a genome-wide multi-centric association study
Bilateral acute retinal necrosis in a patient with multiple sclerosis on natalizumab
Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report
Multiple sclerosis disease activity and disability following discontinuation of natalizumab for pregnancy
Extended interval dosing strategies in multiple sclerosis: insights from natalizumab and ocrelizumab trials
Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study
Immunological and clinical consequences of splenectomy in a multiple sclerosis patient treated with natalizumab
GP6 rs2304166 polymorphism is associated with response to natalizumab in multiple sclerosis patients
Natalizumab May Improve Cognition and Mood in Multiple Sclerosis
Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists
Pharmacogenomics of clinical response to Natalizumab in multiple sclerosis: a genome-wide multi-centric association study
Bilateral acute retinal necrosis in a patient with multiple sclerosis on natalizumab
Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report
Multiple sclerosis disease activity and disability following discontinuation of natalizumab for pregnancy
Extended interval dosing strategies in multiple sclerosis: insights from natalizumab and ocrelizumab trials
Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study
Immunological and clinical consequences of splenectomy in a multiple sclerosis patient treated with natalizumab
GP6 rs2304166 polymorphism is associated with response to natalizumab in multiple sclerosis patients
Natalizumab May Improve Cognition and Mood in Multiple Sclerosis
Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists
Pharmacogenomics of clinical response to Natalizumab in multiple sclerosis: a genome-wide multi-centric association study
Bilateral acute retinal necrosis in a patient with multiple sclerosis on natalizumab
Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report
Multiple sclerosis disease activity and disability following discontinuation of natalizumab for pregnancy
Extended interval dosing strategies in multiple sclerosis: insights from natalizumab and ocrelizumab trials
Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study